Advanced search
Publication Cover
Leukemia & Lymphoma Volume 62, 2021 - Issue 8
Submit an article Journal homepage
346
Views
1
CrossRef citations to date
0
Altmetric
Letters to the Editor

Pseudoprogression of triple-hit diffuse large B-cell lymphoma following polatuzumab vedotin-based salvage therapy

Xin Wanga Department of Medicine, University of Massachusetts Medical School, Worcester, MA, USAORCID Iconhttps://orcid.org/0000-0001-9827-3098
ORCID Icon,
Lacey McIntoshb Division of Oncologic Imaging, Department of Radiology, University of Massachusetts Medical School, Worcester, MA, USA
,
William J. Selovec Department of Pathology, University of Massachusetts Medical School, Worcester, MA, USA
,
Jaroslav Zivnyd Division of Gastroenterology, Department of Medicine, University of Massachusetts Medical School, Worcester, MA, USA
&
Jan Cernye Division of Hematology/Oncology, Department of Medicine, University of Massachusetts Medical School, Worcester, MA, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-6602-5505
ORCID Icon
Pages 2022-2025 | Received 05 Nov 2020, Accepted 18 Feb 2021, Published online: 15 Mar 2021

References

  • Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin’s lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin’s Lymphoma Classification Project . J Clin Oncol. 1998;16(8):2780–2795.
  • Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2020;38(2):155–165.
  • Scott DW, Mottok A, Ennishi D, et al. Prognostic significance of diffuse large B-cell lymphoma cell of origin determined by digital gene expression in formalin-fix paraffin-embedded tissue biopsies. J Clin Oncol. 2015;33(26):2848–2856.
  • Horn H, Ziepert M, Becher C, et al. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood. 2013;121(12):2253–2263.
  • Shingleton JR, Dave SS. Polatuzumab Vedotin: honing in on relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2020;38(2):166–168.
  • Zelenetz AD, Salles G, Mason KD, et al. Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial. Blood. 2019;133(18):1964–1978.
  • Wahl RL, Jacene H, Kasamon Y, et al. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(Suppl_1):122S–150S.
  • Fuh FK, Looney C, Li D, et al. Anti-CD22 and anti-CD79b antibody-drug conjugates preferentially target proliferating B cells. Br J Pharmacol. 2017;174(8):628–640.
  • Jia W, Gao Q, Han A, et al. The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy. Cancer Biol Med. 2019;16(4):655–670.
  • Wang J, Hu Y, Yang S, et al. Role of fluorodeoxyglucose positron emission tomography/computed tomography in predicting the adverse effects of chimeric antigen receptor T cell therapy in patients with non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2019;25(6):1092–1098.
  • Danylesko I, Shouval R, Shem-Tov N, et al. Immune imitation of tumor progression after anti-CD19 chimeric antigen receptor T cells treatment in aggressive B-cell lymphoma. Bone Marrow Transp. 2020. DOI:https://doi.org/10.1038/s41409-020-01156-y
  • Hochmair MJ, Schwab S, Burghuber OC, et al. Symptomatic pseudo-progression followed by significant treatment response in two lung cancer patients treated with immunotherapy. Lung Cancer. 2017;113:4–6.
  • Di Giacomo AM, Danielli R, Guidoboni M, et al. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases. Cancer Immunol Immunother. 2009;58(8):1297–1306.
  • Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30(18):2190–2196.
  • Lee AT, Attygale AD, Sharma RK, et al. LyRIC indeterminate response and immune-mediated pseudoprogression of diffuse large B-cell lymphoma following polatuzumab-based salvage therapy. Br J Haem. 2020;189:e222–e265.
  • Lee JH, Long GV, Menzies AM, et al. Association between circulating tumor DNA and pseudoprogression in patients with metastatic melanoma treated with anti–programmed cell death 1 antibodies. JAMA Oncol. 2018;4(5):717–721.
  • Aide N, Hicks RJ, Le Tourneau C, et al. FDG PET/CT for assessing tumour response to immunotherapy: report on the EANM symposium on immune modulation and recent review of the literature. Eur J Nucl Med Mol Imaging. 2019;46(1):238–250.
  • Unterrainer M, Ruzicka M, Fabritius MP, et al. PET/CT imaging for tumour response assessment to immunotherapy: current status and future directions. Eur Radiol Exp. 2020;4(1):63.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.